Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773267 | 1.00 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CHTR2AHRH1 | |
| SCHEMBL1773270 | 1.00 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CHTR2AHRH1 | |
| SCHEMBL2010329 | 0.85 | HTR2A (0.33) | ADRA2AADRA2BADRA2CHTR2AHRH1 | |
| SCHEMBL6958572 | 0.79 | LTA4H (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4716852 | 0.79 | LTA4H (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13109023 | 0.78 | SIGMAR1 (0.41) | ADRA2AADRA2BADRA2CHTR2AHRH1 | |
| SCHEMBL3757647 | 0.77 | CRHR1 (0.36) | HTR2AALDH1A1 | |
| SCHEMBL2003394 | 0.76 | KMT2A (0.45) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2003396 | 0.76 | KMT2A (0.45) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5654541 | 0.76 | HTR2A (0.36) | ADRA2AADRA2BADRA2CHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3990449-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| CN-114096532-A | Heterocyclic compounds inhibiting tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-112142743-A | Heterocyclic compound, preparation method and application thereof in medicine and pharmacology | 广州诺诚健华医药科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-0944385-B1 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO 3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING HELICOBACTER PYLORI INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AG (DE) | 2002-10-16 | — | — | EP | disclosed |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| EP-0942911-B1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LAB (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6046207-A | FOR INHIBITING ALPHA-1 ADRENORECEPTORS AND TREATING BENIGN PROSTATIC HYPERPLASIA, ALSO CALLED BENIGN PROSTATIC HYPERTROPHY, OR OTHER UROLOGICAL OR GYNECOLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION, NEUROGENIC BLADDER | ABBOTT LABORATORIES | 2000-04-04 | — | — | US | disclosed |
| EP-0944385-A2 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO 3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING $i(HELICOBACTER PYLORI) INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AG (DE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0942911-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | Abbott Laboratories (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5891882-A | TREATING BENIGN PROSTATIC HYPERPLASIA OR OTHER UROLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION AND NEUROGENIC BLADDER, OR GYNECOLOGICAL SYNDROMES SUCH AS DYSMENORRHEA | ABBOTT LABORATORIES (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998026768-A2 | USE OF 7-(1-AMINOMETHYL-2-OXA-7-AZA-BICYCLO[3.3.0]OCT-7-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES FOR TREATING HELICOBACTER PYLORI INFECTIONS AND THE GASTRODUODENAL DISEASES ASSOCIATED THEREWITH | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998024791-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | ADRA2A 2055/4885ADRA2B 2480/4885ADRA2C 1337/4885 |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | ADRA2A 4233/4885ADRA2B 4290/4885ADRA2C 3700/4885 |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | ADRA2A 64/4885ADRA2B 108/4885ADRA2C 31/4885 |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | ADRA2A 2502/4885ADRA2B 1705/4885ADRA2C 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.